Published in
BMJ Publishing Group, BMJ, mar28 1(348), p. g2296-g2296
DOI: 10.1136/bmj.g2296
Links
- ORCID
- ORCID
- BMJ Publishing Group | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.bmj.com] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study
Journal article published in 2014 by
Sigrid Carlsson 
,
Melissa Assel,
Daniel Sjoberg,
David Ulmert,
Jonas Hugosson,
Hans Lilja,
Andrew Vickers
,
Melissa Assel,
Daniel Sjoberg,
David Ulmert,
Jonas Hugosson,
Hans Lilja,
Andrew Vickers
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Objective To determine the relative risks of prostate cancer incidence, metastasis, and mortality associated with screening by serum prostate specific antigen (PSA) levels at age 60.